文献速递骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌

睾酮与男性骨骼健康:相互作用的谜题

Testosterone and Male Bone Health: A Puzzle of Interactions.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本综述探讨性类固醇在男性骨骼发育与维护中的作用,重点分析睾酮替代治疗(TRT)对骨密度和骨折风险的影响,并总结T-Trial Bone、T4Bone和TRAVERSE Fracture等主要试验的发现。TRT可改善骨密度,但对骨折风险的影响尚无定论;TRAVERSE Fracture试验的意外发现提示需谨慎,抗骨吸收治疗仍是男性骨质疏松的一线治疗。

要点

  • 睾酮主要驱动男性皮质骨生长和骨膜扩张,雌二醇(E2)对骨小梁形成和抑制骨吸收至关重要。
  • TRT可改善骨密度,但对骨折风险的影响尚无定论。
  • TRAVERSE Fracture试验的意外发现提示需谨慎,抗骨吸收治疗仍是男性骨质疏松的一线治疗。

核心结论

  • TRT可改善骨密度,但其对骨折风险的影响尚无定论。
  • TRAVERSE Fracture试验的意外发现强调需谨慎,并确认抗骨吸收治疗仍是男性骨质疏松的一线治疗。

研究设计与样本

  • 本综述探讨男性性腺功能减退与骨质疏松的联系,重点讨论TRT及T-Trial Bone、T4Bone和TRAVERSE Fracture等主要试验的发现。

主要发现

  • 睾酮主要驱动男性皮质骨生长和骨膜扩张,尤其在青春期;雌二醇(E2)对骨小梁形成和抑制骨吸收必不可少。
  • 芳香化酶抑制剂和雄激素剥夺治疗可导致雌激素和雄激素阻断,常引起显著骨丢失。
  • TRT已显示可改善骨密度,但对骨折风险的影响尚无定论。
  • TRAVERSE Fracture试验的意外发现强调需谨慎,并确认抗骨吸收治疗仍是男性骨质疏松的一线治疗。

关键数值与推荐

  • TRT可改善骨密度,但对骨折风险的影响尚无定论。
  • 抗骨吸收治疗仍是男性骨质疏松的一线治疗。

临床怎么用

  • 抗骨吸收治疗仍是男性骨质疏松的一线治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sex steroids are pivotal in skeletal development and maintenance throughout life. Testosterone primarily drives male cortical bone growth and periosteal expansion, particularly during puberty, while estradiol (E2) is essential for trabecular bone formation and inhibiting resorption. The conversion of testosterone to dihydrotestosterone and E2, the transport proteins, the somatotropic axis, and the nonandrogenic functions of the testis underscore the intricate interplay protecting male bone health. Clinical models, including estrogen resistance, aromatase deficiency, and complete androgen insensitivity syndromes, highlight E2's critical role in maintaining male bone integrity. The use of aromatase inhibitors and androgen deprivation therapy reveals the adverse effects of estrogen and androgen blockade, often resulting in substantial bone loss. Gender-affirming hormone therapies provide further insights into testosterone's influence on cortical bone during development and the maintenance role of sex steroids in adulthood. This review digs into the link between male hypogonadism and osteoporosis, emphasizing testosterone replacement therapy (TRT) and findings from major trials, including T-Trial Bone, T4Bone, and TRAVERSE Fracture. While TRT has been shown to improve bone mineral density, its effect on fracture risk remains inconclusive. Unexpected findings from the TRAVERSE Fracture trial highlight the importance of caution and confirm that antiresorptive therapies remain the first-line treatment for male osteoporosis. Investigating the synergistic effects of combining TRT with antiresorptive therapies, the effect of therapeutic timing on peak bone mass accrual, and the role of confounders in fracture risk are promising areas for future research to optimize male skeletal health.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tenuta M, Hasenmajer V, Gianfrilli D, et al. Testosterone and Male Bone Health: A Puzzle of Interactions. J Clin Endocrinol Metab. 2025. PMID: 40120082. doi:10.1210/clinem/dgaf191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。